Key Facts Surrounding This News Item
- MDGL had a POWR Rating of B (Buy) coming into today.
- MDGL was -1.40% below its 10-Day Moving Average coming into today.
- MDGL was 3.58% above its 20-Day Moving Average coming into today.
- MDGL was 1.94% above its 50-Day Moving Average coming into today.
- MDGL was 47.18% above its 100-Day Moving Average coming into today.
- MDGL was 96.50% above its 200-Day Moving Average coming into today.
- MDGL had returned +210.74% year-to-date leading up to today’s news, versus a +19.42% return from the benchmark S&P 500 during the same period.
More Info About Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania. View our full MDGL ticker page with ratings, news, and more.
Try StockNews.com Premium Today!
Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!